11.29.23 -- Vaccine Maker's Toolkit: Strategies For Manufacturing And Supply Management

Compare in-house buffer preparation to outsourcing buffer preparation activities, highlighting the potential for optimizing resources and mitigating risks.

Learn about different strategies for ensuring the reliable delivery of health technologies with a focus on vaccines, mAbs, and new modalities manufactured by biotechnology companies and institutes.

Watch as biopharmaceutical experts discuss the various obstacles teams face when leading the operations and manufacturing of advanced medicines and the strategies to overcome them.

As critical raw materials for viral vector production, plasmids are in high demand. Finding an experienced, GMP-grade plasmid supplier for your process can mitigate risk and yield reliable results.

The decision whether to develop and manufacture a drug in-house or to outsource comprises numerous elements, including costs, timelines, production capacity, and available resources.

Read this expert comparative coverage analysis study performed to assess the reactivity of anti-E. coli HCP antibodies that support ELISA kits.

Discover how manufacturing research-grade Cas enzymes in an ISO 13485 certified facility enables a seamless transition to a cGMP product as you progress into the clinic.

In batch processing operations, the combination of numerous concurrent and independent steps can lead to bottlenecks. Learn how to find the root cause and solution for every operational delay.

Meeting the growing demand for aseptic fill/finish operations requires specialized expertise, appropriate equipment, and innovations in both emerging technology and business models.

Explore key advice for fulfilling qualified person requirements and minimizing supply chain risk and clinical trial disruption under the new rules of the U.K.’s Trade and Cooperation Agreement with the EU.

Biopharmaceutical tech transfer, critical to the successful development and manufacture of an asset, requires careful planning and evaluation to meet project timelines for scale-up and GMP.

The experience and expertise of the CMO is crucial to avoid the risk of cross-contamination of the drug product, as failures or weaknesses in this process can pose risk to the end user.

The FDA holds strict requirements for magnetic bead removal prior to therapeutic use. Learn how this system effectively separates cells from microcarriers and provides maximum cell recovery.

Learn about emerging technologies and approaches for intensifying mAb purification and diversifying bispecific antibody, fragment, and ADC pipelines.

Review the demonstration of how a bioreactor and bioreactor system combination was used to isolate exosomes after culturing human adipose-derived stem cells in suspension on microcarriers.

Examine how a proprietary technology ensures high levels of accurate HC-LC pairing without detriment to critical quality attributes such as titer, binding affinity, stability, and immunogenicity.

Explore some of the most relevant engineering activities that are necessary to successfully transfer a product from vial into a prefilled syringe presentation.